Newleos Therapeutics Announces Poster Presentation to be Featured at the 2025 World Congress of Biological Psychiatry September 11, 2025
Newleos Therapeutics Announces Poster Presentation to beFeatured at the 2025 World Congress of BiologicalPsychiatry September 9, 2025
Evommune Announces Late-Breaker Presentation of Phase 2 Data for EVO756 in Chronic Inducible Urticaria at Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress September 3, 2025
Evommune Initiates Phase 2b Trial of its Oral MRGPRX2 Antagonist, EVO756, in Adults with Moderate to Severe Atopic Dermatitis August 27, 2025
